Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EPRX NASDAQ:GNFT NASDAQ:HYPD NASDAQ:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPRXEupraxia Pharmaceuticals$5.78-1.5%$5.60$2.31▼$7.19$211.09M1.51209,037 shs42,286 shsGNFTGENFIT$4.24+1.9%$4.04$2.55▼$6.23$208.01M1.1810,873 shs2,591 shsHYPDHyperion DeFi$7.27+6.8%$8.53$0.85▼$47.33$47.39M2.57776,322 shs459,875 shsVORVor Biopharma$29.00-0.2%$36.55$2.62▼$65.80$199.18M2.07528,267 shs613,740 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPRXEupraxia Pharmaceuticals-1.53%-4.78%+7.43%+9.26%+133.06%GNFTGENFIT+1.92%+0.47%+0.93%+11.14%-32.48%HYPDHyperion DeFi+6.75%-9.46%-40.70%-43.56%-83.48%VORVor Biopharma-0.21%-7.14%-4.61%-34.39%+2,899,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPRXEupraxia Pharmaceuticals$5.78-1.5%$5.60$2.31▼$7.19$211.09M1.51209,037 shs42,286 shsGNFTGENFIT$4.24+1.9%$4.04$2.55▼$6.23$208.01M1.1810,873 shs2,591 shsHYPDHyperion DeFi$7.27+6.8%$8.53$0.85▼$47.33$47.39M2.57776,322 shs459,875 shsVORVor Biopharma$29.00-0.2%$36.55$2.62▼$65.80$199.18M2.07528,267 shs613,740 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPRXEupraxia Pharmaceuticals-1.53%-4.78%+7.43%+9.26%+133.06%GNFTGENFIT+1.92%+0.47%+0.93%+11.14%-32.48%HYPDHyperion DeFi+6.75%-9.46%-40.70%-43.56%-83.48%VORVor Biopharma-0.21%-7.14%-4.61%-34.39%+2,899,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEPRXEupraxia Pharmaceuticals 2.86Moderate Buy$11.0090.31% UpsideGNFTGENFIT 2.00Hold$7.0065.09% UpsideHYPDHyperion DeFi 1.80Reduce$2.00-72.49% DownsideVORVor Biopharma 2.45Hold$77.83168.39% UpsideCurrent Analyst Ratings BreakdownLatest HYPD, EPRX, VOR, and GNFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/15/2025VORVor BiopharmaBaird R WSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/15/2025VORVor BiopharmaRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$20.00 ➝ $64.0010/14/2025GNFTGENFITWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/13/2025VORVor BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell10/8/2025EPRXEupraxia PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025HYPDHyperion DeFiWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VORVor BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025EPRXEupraxia PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025GNFTGENFITWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025HYPDHyperion DeFiWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025VORVor BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AN/AGNFTGENFIT$76.77M2.76$0.07 per share59.47$1.50 per share2.83HYPDHyperion DeFi$60K843.32N/AN/A($695.52) per share-0.01VORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEPRXEupraxia Pharmaceuticals-$25.50M-$0.85N/AN/AN/AN/A-626.84%-118.31%11/6/2025 (Estimated)GNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/AN/AHYPDHyperion DeFi-$49.82M-$58.40N/AN/AN/A-62,238.41%-876.25%-181.67%N/AVORVor BiopharmaN/A-$273.20N/A∞N/AN/AN/AN/AN/ALatest HYPD, EPRX, VOR, and GNFT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025N/AEPRXEupraxia Pharmaceuticals-$0.23N/AN/AN/AN/AN/A8/13/2025Q2 2025HYPDHyperion DeFiN/A-$2.50N/A-$2.50N/AN/A8/12/2025Q2 2025EPRXEupraxia Pharmaceuticals-$0.21-$0.26-$0.05-$0.26N/AN/A8/12/2025Q2 2025VORVor Biopharma-$11.40-$43.60-$32.20-$12.56N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEPRXEupraxia PharmaceuticalsN/A8.728.72GNFTGENFIT0.093.743.74HYPDHyperion DeFi0.200.910.91VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEPRXEupraxia PharmaceuticalsN/AGNFTGENFIT2.24%HYPDHyperion DeFi25.84%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipEPRXEupraxia PharmaceuticalsN/AGNFTGENFIT4.20%HYPDHyperion DeFi10.86%VORVor Biopharma0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEPRXEupraxia Pharmaceuticals2935.96 millionN/AN/AGNFTGENFIT12050.00 million47.90 millionNot OptionableHYPDHyperion DeFi406.96 million6.20 millionNo DataVORVor Biopharma1406.85 million6.82 millionN/AHYPD, EPRX, VOR, and GNFT HeadlinesRecent News About These CompaniesInsider Selling: Vor Biopharma (NASDAQ:VOR) Major Shareholder Sells 2,021 Shares of StockOctober 18 at 6:14 AM | insidertrades.comVor Biopharma (NASDAQ:VOR) Upgraded at Robert W. BairdOctober 18 at 2:39 AM | americanbankingnews.comVor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025October 17 at 8:00 AM | globenewswire.comFinancial Survey: Vor Biopharma (NASDAQ:VOR) vs. Inhibikase Therapeutics (NASDAQ:IKT)October 17 at 2:41 AM | americanbankingnews.comVor Biopharma (NASDAQ:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 22,006 SharesOctober 16 at 7:17 PM | marketbeat.comInsider Selling: Vor Biopharma (NASDAQ:VOR) Major Shareholder Sells 33,668 Shares of StockOctober 16 at 7:16 PM | marketbeat.comVor Biopharma (NASDAQ:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 40,983 SharesOctober 16 at 7:16 PM | marketbeat.comVor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of MedicineOctober 16 at 10:03 AM | markets.businessinsider.comVor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of MedicineOctober 16 at 8:00 AM | globenewswire.comVor Biopharma (NASDAQ:VOR) Upgraded at Baird R WOctober 16 at 6:51 AM | marketbeat.comVor Biopharma (NASDAQ:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 22,006 SharesOctober 16 at 5:09 AM | insidertrades.comBaird Upgrades Vor Biopharma (VOR)October 15 at 3:05 PM | msn.comVor Biopharma (NASDAQ:VOR) Upgraded by Robert W. Baird to "Outperform" RatingOctober 15 at 8:24 AM | marketbeat.comVor Biopharma (NASDAQ:VOR) Lowered to "Strong Sell" Rating by Zacks ResearchOctober 15 at 7:45 AM | marketbeat.comVor Biopharma Shares Climb After Positive Phase 3 Results for Sjögren’s TreatmentOctober 14, 2025 | msn.comVor Biopharma stock rises after positive Phase 3 results for Sjögren’s treatmentOctober 14, 2025 | za.investing.comTelitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025October 14, 2025 | globenewswire.comVor Biopharma Inc. (NASDAQ:VOR) Given Consensus Rating of "Hold" by BrokeragesOctober 13, 2025 | americanbankingnews.comVor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Hold" from AnalystsOctober 13, 2025 | marketbeat.comReprogrammed Interchange Llc Sells 48,884 Shares of Vor Biopharma (NASDAQ:VOR) StockOctober 11, 2025 | marketbeat.comVor Biopharma (NASDAQ:VOR) Major Shareholder Sells $2,549,123.94 in StockOctober 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhich National Chains Do People Wish Were in Their State? [2025 Survey]By MarketBeat Staff | September 30, 2025Alphabet: After Its Best Quarter in Decades, Is It Time to Buy?By Ryan Hasson | October 3, 2025Why Seagate Is Wall Street's New Favorite AI Infrastructure PlayBy Jeffrey Neal Johnson | September 18, 2025Beam Global Gets Buy Rating With 101% Upside PotentialBy Nathan Reiff | September 27, 2025Ford Set to Outpace GM With Tariff Tailwinds and EPS MomentumBy Gabriel Osorio-Mazilli | September 24, 2025HYPD, EPRX, VOR, and GNFT Company DescriptionsEupraxia Pharmaceuticals NASDAQ:EPRX$5.78 -0.09 (-1.53%) Closing price 10/17/2025 03:59 PM EasternExtended Trading$5.76 -0.02 (-0.35%) As of 10/17/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.GENFIT NASDAQ:GNFT$4.24 +0.08 (+1.92%) Closing price 10/17/2025 03:52 PM EasternExtended Trading$4.19 -0.05 (-1.16%) As of 10/17/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Hyperion DeFi NASDAQ:HYPD$7.27 +0.46 (+6.75%) As of 10/17/2025 04:00 PM EasternEyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Vor Biopharma NASDAQ:VOR$29.00 -0.06 (-0.21%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$27.92 -1.08 (-3.72%) As of 10/17/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
